Home MarketJubilant Life Sciences Ltd.

Jubilant Life Sciences Ltd. Stock Info: As on 2017-08-24 11:54:59

Nse

730.00

10.55(1.47%)
Change%
52 Week Range
495.25
23.00
878.00
12.00
Open712.20
Day's Range575.56 - 863.34
Value Traded (in ₹ Cr.) 17.45

Bse

733.55

14.35(2.00%)
Change %
52 Week Range
495.50
23.00
879.10
12.00
Open723.50
Day's Range575.36 - 863.04
Value Traded (in ₹ Cr.) 2.57

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 6,970,380.00 4.38%
IndianPromoters 79,080,676.00 49.65%
Mutual Funds/UTI 5,637,657.00 3.54%
FII 30,357,772.00 19.06%
Employee 0.00 0.00%
Public 21,271,493.00 13.35%
Government 0.00 0.00%
Others 9,509,551.00 5.97%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 2.50
Basic EPS (Rs.) 4.96
Cash EPS 10.42
BVPerShare Excl 124.45
Operating Revenue 166.74
PBDITPerShare 25.27
Dividend 3.00
NPPerShare 4.96
Current Ratio 0.89
Quick Ratio 0.49
PriceToBV 3.35
Earnings 0.01
PBDIT Margin 15.15
PBT Margin 3.44
NP Margin 2.97
Return On Assets 1.75
Retention Ratios 39.56
Parameter Mar-16 (₹ Cr.) Yoy%change
Total Income 2,717.91
Total Expenses 2,604.57
EBITDA 402.63
PBT 91.41
PAT 79.07
Net Income 79.07
More
Parameter Mar-16 (₹ Cr.) 6M % change
Total Income 1,289.82
Total Expenses 1,152.62
EBITDA 93.58
PBT 30.19
PAT 20.76
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-16 (₹ Cr.) Yoy%change
Total share capital 15.93
Net worth 1,982.50
Investments 1,706.83
Total Liability 4,503.45
Total debt 1,556.53
Net block 1,446.95
Total Assets 4,503.45
Parameter Mar-16 (₹ Cr.) 6M % change
Total share capital 15.93
Net worth 1,982.50
Investments 1,706.83
Total Liability 4,503.45
Total debt 1,556.53
Net block 1,446.95
Total Assets 4,503.45
Company Curr Price Prev. Close Change% W's Low/High

Aarti Drugs Ltd.

514 517.25 -0.63
485533.8

Abbott India Ltd.

4277.95 4298.4 -0.48
42104325

Ajanta Pharma Ltd.

1235 1191.75 3.63
11351224.8

Albert David Ltd.

317.5 312.9 1.47
305.45318.45

Alembic Ltd.

39.6 37.3 6.17
36.838.3

Alembic Pharmaceuticals Ltd.

518.05 505.75 2.43
505525.75

Alkem Laboratories Ltd.

1799 1805.45 -0.36
17431834.85
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

127.3 125.8 1.19
110.55129.9

Aarti Drugs Ltd.

511.05 519.3 -1.59
488530

Aayush Food & Herbs Ltd.

45.4 47.7 -4.82
42.8548.55

Abbott India Ltd.

4285 4289.15 -0.1
41874341.25

ABL Bio-Technologies Ltd.

0.81 0.78 3.85
0.750.81

Addlife Pharma Ltd.

0.46 0 0
0.460.5

Adinath Bio-Labs Ltd.

0.3 0.31 -3.23
0.30.3
More
Parameter Mar-16(in ₹ Cr.)
Cash from operating activities 140.37
Cash from investing activities 521.70
Cash from financing activities -760.51
Net change in cash -98.44

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
Motilal Oswal MOSt Focused Multicap 35 Fund 4.20%
Motilal Oswal MOSt Focused Midcap 30 Fund 4.70%
L&T India Value Fund - Regular Plan 0.59%
Motilal Oswal MOSt Focused Dynamic Equity Fund 2.79%
Motilal Oswal Most Focused Long Term Fund 4.29%
Edelweiss Mid and Small Cap Fund 0.75%

Lupin launches generic Seroquel XR tablets in US

Pharma major, Lupin announced that the company has received approval from the United States Food and Drug Administration (USFDA) for Quetiapine Fumarate Extended-Release Tablets. The tablets are the AB rated generic equivalent of AstraZeneca Pharmaceuticals LP’s Seroquel XR tablets, 50 mg, 150 mg, 200 mg, 300 mg and 400 mg, the company said in a filing to the Bombay Stock Exchange. It is indicated for the treatment of schizophrenia; acute manic or mixed episodes in bipolar I disorder alone or as an adjunct to lithium or divalproex; acute depressive episodes in bipolar disorder; maintenance treatment of bipolar I disorder, as an adjunct to lithium or divalproex an as an adjunctive therapy to antidepressants for the treatment of major depressive disorder.

23-08-2017 17:17

Balaji Telefilms allots shares aggregating Rs 413 cr to RIL

Mukesh Ambani-led Reliance Industries on Wednesday said that Balaji Telefilms has allotted 2.52 crore equity shares of Rs 2 each to the company on August 22, 2017 at a market price of Rs 164 per share amounting to Rs 413.28 crore. “The company has been allotted 2.52 crore equity shares of Rs 2 each fully paid up of Balaji Telefilms on August 22, 2017 at a market price of Rs 164 per share, including premium of Rs 162 per share, aggregating Rs 413.28 crore on preferential allotment basis constituting 24.92 per cent of the post allotment paid-up equity share capital of Balaji Telefilms,” said Reliance Industries in a filing to the Bombay Stock Exchange. As on June 20, the board of directors of Reliance Industries had approved an investment in Balaji Telefilms amounting to Rs. 413.28 crore. This investment in content production (including digital content) is in line with RIL’s commitment to invest and grow in telecom digital and media businesses. Ahead of the announcement, shares of the company closed day’s trade at Rs 1581.30 apiece, up 1.15 per cent, on the BSE.

23-08-2017 16:12

SMS Pharma completes inspection of Telengana unit by PMDA

SMS Pharmaceuticals said that it successfully completed inspection of Telengana plant by Japanese regulator. “The company successfully completed inspection by Pharmaceuticals and Medical Devices Agency (PMDA) Japanese Authorities for the manufacturing facility-Unit II, located in Hyderabad – Telangana,” it said in a filing to the Bombay Stock Exchange. The inspection was done during the period July 25 – 27. The inspection was focussed on general GMP (Good Manufacturing Practice) inspection of the site. The inspection has been concluded with no critical/major observation, it said. Meanwhile, shares of the company closed trading at Rs 82 apiece, up 12.33 per cent from the previous close on BSE.

23-08-2017 16:03

Cabinet okays closure of Bharat Wagon & Engineering Company

The Cabinet Committee on Economic Affairs, chaired by the Prime Minister Shri Narendra Modi, has approved the proposal of Ministry of Railways to close the Bharat Wagon and Engineering Company Limited (BWEL) - a Central Public Sector Enterprise (CPSE) under Ministry of Railways. 626 employees of BWEL will be benefitted from the voluntary retirement scheme to be offered at 2007 pay scale. The Government will have to provide one time grant off 151.18 crore towards severance package and for clearing the current liabilities of the company, said an official statement. This measure will stop flow of financial support from public funds for carrying on the operations of sick/loss making BWEL resulting in savings for the Government. The implementation will be done as per the timelines prescribed in the guidelines issued by Department of Public Enterprises (DPE) on time bound closure of sick/loss making CPSEs. In view of the continues poor physical and financial performance of the company for more than 10 years, in spite of financial assistance and other support provided by Ministry of Railways combined with low probability of its revival in future, Bharat Wagon and Engineering Co. Ltd. is being wound up.

23-08-2017 15:52

Esaar India board approves consolidation of equity shares

Esaar India on Wednesday said that its board has approved consolidation of equity shares of the company from Rs 1 each fully paid up into Rs 10 each fully paid up. “In the meeting of the board of directors of the company on August 23, 2017, it has approved to consolidate face value of equity shares of the company from Rs 1 each fully paid up into Rs 10 each fully paid up,” Esaar India said in a filing to the Bombay Stock Exchange. The board has also approved the proposal to alter memorandum of association of the company to that effect, subject to approval of members at ensuing general meeting and other necessary approvals, it added.

23-08-2017 15:36

Jubilant gets NDA approval for Drax Exametazime

Pharma major, Jubilant Life Sciences said that Jubilant Pharma Limited, a material wholly owned subsidiary of the Company, through one of its wholly owned subsidiaries, Jubilant Draximage Inc, Montreal, Canada, has received U.S. Food and Drug Administration (USFDA) approval for Drax Exametazime, for its New Drug Application (NDA). This approved new drug application is indicated for leukocyte (white blood cell) labeled scintigraphy as an adjunct in the localization of intra- abdominal infection and inflammatory bowel disease, the company said in a filing to the Bombay Stock Exchange. “This is the 6th approval that we have received from the USFDA during the current financial year,” the company said. As on June 30, 2017 , Jubilant had a total of 84 ANDAs for Oral Solids filed in the US, of which 53 had been approved and 12 Injectable filings of which 9 had been approved. Meanwhile, shares of the company were trading at Rs 704.80 apiece, up 0.06 per cent from the previous close at 14:55 hours on BSE.

21-Aug-2017 02:55 PM

Jubilant Life Scienc - Press Release

Jubilant Life Sciences Limited has informed the Exchange regarding a press release dated August 21, 2017, titled Jubilant receives NDA approval for Drax Exametazime.

21-Aug-2017 02:44 PM

Jubilant Life Scienc - Updates

Jubilant receives NDA approval for Drax Exametazime

21-Aug-2017 02:43 PM

Jubilant Life Sciences Q1 net profit up 6.24% at Rs 22.29 cr

The company reported standalone net profit of Rs 22.29 crore for the quarter ended June 30, 2017 as compared to Rs 20.98 crore in the same period last year, registering a year-on-yeargrowthof 6.24 per cent. Net revenue of the company rose moderately by 15.01 per cent at Rs 664.15 crore in April-June quarter of this fiscal as against Rs 577.49 crore in the corresponding period last year. During April-June quarter, operating expenses increased by 21.58 per cent to Rs 601.65 crore from Rs 494.87 crore in year ago period. Other Income grew by 126.32 per cent at Rs 10.75 crore versus (Jun'16 Rs 4.75 crore). Operating Profit slipped by 21.62 per cent to Rs 72.16 crore as against Rs 92.06 crore in the year ago period, while Operating Profit Margin (OPM) contracted year-on-year to 31.81 per cent in June quarter. Interest declined by 20.40 per cent y-o-y to Rs 35.31 crore, while Taxation decreased by 54.16 per cent at Rs 5.12 crore (Jun'16 Rs 11.17 crore).

09-Aug-2017 07:24 PM

Jubilant Life Scienc - Updates

Submission of copies of newspaper advertisements for 39th Annual General Meeting / Book Closure and e-Voting information

08-Aug-2017 03:08 PM

Jubilant Life Scienc - Updates

Jubilant receives NDA approval for Drax Exametazime

21-Aug-2017 02:43 PM

Jubilant Life Scienc - Updates

Submission of copies of newspaper advertisements for 39th Annual General Meeting / Book Closure and e-Voting information

08-Aug-2017 03:08 PM

Jubilant Life Scienc - Fixes Book Closure for Dividend & AGM

Jubilant Life Sciences Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from August 19, 2017 to August 29, 2017 (both days inclusive) for the purpose of Payment of Dividend & 39th Annual General Meeting (AGM) of the Company to be held on August 29, 2017.

08-Aug-2017 12:29 PM

Corporate Details

About Management

YEAR EVENTS 1978 - The Company was incorporated on 21st June, in Uttar Pradesh. The Company manufacture Vinyl Acetate Monomer (VAM). The Company was promoted by A.B. Bofors (Swedish Multinational), Hindustan Wires Ltd., and Mr. M.L. Bhartia. - The Company entered into a technical collaboration agreement with Noble Chematur Division of A.B. Bofors, Sweden for the supply of know-how and basic engineering for the manufacture of vinyl acetate monomer. 1981 - 1,200 No. of equity shares subscribed for by the signatories to the Memorandum of Association. 34,63,800 No. of equity and 38,500 Pref. shares issued through a prospectus during Mar./Apr. 1982, 19,250 Pref. shares each reserved and allotted to UPSIDC and PICUP. 6,08,370 No. of equity shares reserved and allotted to Indian private promoters and their associates, 6,55,430 No. of equity shares reserved and allotted to AB Brothers of Sweden and 22,00,000 No. of equity shares offered at par for public subscription. Pref. shares redeemable during 28.5.1993/96. 1982 - 6,93,000 Rights Equity shares issued at par in prop. 1:5 (only 5,52,043 shares taken up). The remaining 1,40,357 shares allotted on private placement basis (including 96,800 shares to non-residents). 1983 - Another technical collaboration agreement was signed with Crown Decorative Products Ltd., U.K., and Reed International Company for the manufacture of high pressure emulsions i.e., Polyvinyl Acetate Emulsions. This project was commissioned in 1985-86. - During November, the Company promoted `India Glycols Ltd.' to take up the implementation of a project to manufacture Mono Ethylene Glyco (MEG) at Kashipur, U.P., in technical collaboration with Scientific Design Co. Int., U.S.A. Commercial production commenced on 1st January, 1990. 1984 - A technical collaboration agreement was signed with Technimont Spa of Italy for the manufacture of polyvinyl alcohol with an installed capacity of 2,000 tonnes per annum. The unit was commissioned in July 1991, with an installed capacity of 650 MT per annum. During 1991, the capacity was doubled to 1,400 tonnes per annum. The Company proposed to enhance the capacity of 2,000 MT per annum by installing additional equipment. 1985 - Vam Leasing Ltd., and Vam Investments Ltd., were incorporated as wholly owned subsidiaries of the Company. 1986 - 10,06,180 No. of equity shares issued at par to financial institutions on conversion of loans. 1987 - The Company decided to set up a plant to recover carbon dioxide in collaboration with Hydrogas Denmart a.s. of Denmark and manufacture to dry ice. The plant was commissioned in 1989. A biogas plant was also set up in collaboration with Biotim N.V. of Belgium as a part of energy conservation programme. - The Company also promoted `Insilco Ltd.' jointly with Degussa AG of West Germany for the manufacture of spray dried silica. The project was expected to go on stream by the middle of 1991. - Applications were also submitted to Government for increasing the production capacity of vinyl acetate monomer from 10,000 tonnes to 20,000 tonnes per annum. - In order to part finance the vinyl acetate monomer project, during January, the company privately placed with financial institutions, 15% non-convertible debentures worth Rs 1.00 crores. These debentures are redeemable at a premium of 5% in three equal annual instalments commencing on 27th April, 1993. - The Company privately placed with financial institutions 14% non-convertible debentures worth Rs 1.50 crores. These debentures are redeemable in full at a premium of 5% on 29th December, 1994. 1989 - A synthetic wood adhesive "Vamicol" was launched in January and liquid and dry carbon-di-oxide (dryice) were launched in March. The company installed another new boiler of capacity 25 tonnes steam/hour based on the fluidised bed technology to eliminate air pollution. - The Company privately placed with financial institutions 14% non-convertible debentures worth Rs 10 crores. These debentures are redeemable in full at a premium of 5% on 25th June, 1996. 1990 - The Company commissioned a plant with an installed capacity of 500 tonnes per annum for the manufacture of pyridine and picoline. - The Company undertook to expand the production capacities of vinyl acetate monomer and its intermediaries i.e., acetic anhydride and acetic acid. The expanded capacities were commissioned in October 1990. - The Company privately placed 14% redeemable non-convertible debentures of Rs 100 each aggregating Rs 5.00 crores. These debentures are redeemable at a premium of 5% in three equal annual instalments commencing on 11th September, 1996. - During the year, another 5,00,000-14% redeemable non-convertible debentures of Rs 100 each were privately placed with a provision to redeem at a premium of 5% in three equal instalments commencing on 29th March, 1997. 1992 - Ramganga Fertilizers Ltd. (RFL) was amalgamated with the company effective 1st April, as per BIFR Scheme. As per the scheme of amalgamation 2,56,522 No. of equity shares of Rs 10 each were issued at par to the shareholders of erstwhile RFL in the ratio of one equity share of the company for every 10.35 No. of equity share of Rs 10 each fully paid-up of the erstwhile RFL. 1995 - A technical collaboration agreement was signed with Kemira Coatings Ltd., U.K., to manufacture wood finishes a polymer based product. Another agreement was also signed with M/s. Teutoburg, Germany to manufacture construction chemicals in its plant at Gajraula. - The company proposed to install an additional turbine generator with a capacity of 5.5 MW in view of high and frequently incidence of power failure and fluctuation. The company also proposed to increase the installed capacity of Pyridine & Picolines by 4,000 tonnes per annum to meet the increasing demand for the products. - 2,56,522 No. of equity shares issued to the shareholders of erstwhile RFL on merger of the said company with company. 1996 - The Company proposed to open offices in Singapore to cater to the need of S.E. Asia & China & European markets. With a view to tackling the power failure and fluctuations, the company proposed to instal a turbine generator with a capacity of 5.5 MW. - The company made a capital expenditure of Rs 26.40 crores for taking up projects such as Pyridene & Picolines, wood furnisher, construction chemicals with the intention of saving valuable foreign Exchange. It was also proposed to modernise its sulphuric acid plant. With a view to saving energy the company proposed to instal biogas fired boiler. 1997 - The Company faced a sharp decline in sales realisation of Acetic Acid and VAM, due to a combination of the South East Asian financial debacle and the large capacity build up of Acetic Acid and VAM in South Korean and Singapore. - The company has embarked on a substantial capital expenditure programme to enhance capacities of existing products and also manufacture new products. - Vam Organic Chemicals Ltd has registered a 8.97 per cent increase in net profit for the year ended March 31, 1997 at Rs.23.07 crores as compared to Rs.21.17 crores in the previous year. 1998 - Vam Organics Chemicals has introduced a specialist adhesive Vam Bond 2001. - The dry silica venture, jointly promoted by Vam Organics and Degussa AG of Germany with a 34 per cent stake each has not been doing too well. - The company's performance has been affected due to low international prices, steady increase in prices of major raw materials and sluggish growth in the overall market. - VAM Organic Chemicals Ltd (VOCL) proposes to merge group companies Anichem India Ltd (AIL) and Enpro Speciality Chemicals Ltd (ESCL) with itself. - A planned shut-down of the fertiliser plant was undertaken for 72 days in the quarter for revamping. It also increased its installed capacity from 125 tonnes per day to 175 tonnes per day for sulphuric acid. A captive power plant of 12.45 MW was commissioned in July this year. - VAM Organic Chemicals Ltd is exploring the possibility of entering into areas such as sugar, speciality chemicals and bulk drugs. - The non-convertible debenture programme of Vam Organic Chemicals Ltd has been downgraded by ICRA to LA- LAA-. Vam was the largest player in the alcohol-based organic chemical industry with the largest capacities in the country for most of its products including acetic acid, acetic anhydride, etc. 1999 - VAM Organic Chemicals Ltd (VOCL) has proposed to consolidate and improve its existing position in the chemical industry in the current fiscal. - VOCL has also commissioned the units of Polychem Ltd, manufacturing alcohol-based chemicals in May. - The Company's 22,500 tonnes per annum formaldehyde plant has been commissioned, permitting it to export greater quantities of picolines and pyridines. It has also installed new boilers and increased the capacities of existing plants. 2000 -Enters the Bio / chemo informatics arena by setting up Jubilant Biosys Ltd. 2001 -New corporate identity: Jubilant Organosys Ltd. reflecting changed corporate and business profile 2002 -Acquires the Active Pharmaceutical Ingredients business 2003 -Trading symbol of Jubilant Organosys Limited is changed from 'VAMORGANIC ' to 'JUBILANT' -Jubliant Securites Pvt. Ltd. & Jubliant Capital Pvt. Ltd has acquired 4,38,068 (2.99% of total paid up capital) equity shares. -Mr. H K Khan (Retd. IAS) has been appointed as additional director with effect from November 05, 2003 on the Board. 2004 -Jubilant Organosys Limited has informed that the Board of Directors at their meeting held on January 9, 2004 have approved for voluntary delisting of equity shares of the Company from The Delhi Stock Exchange Association Limited, The Calcutta Stock Exchange Association Limited, Kolkata and the Uttar Pradesh Stock Exchange Association Limited subject to the approval of shareholders by special resolution. -Jubilant Organosys acquires generic pharma Companies in Europe -Jubilant Organosys signs international contracts worth US$ 60 million in CRAMS for the year 2007 2005 -Acquired pharmaceutical company in USA involved in off patent drug development and supply, and owns US FDA approved manufacturing facility for solid dosage forms. -Acquires full service Clinical Research Organization in USA involved in providing clinical research services, data management, biostatistics and contract staffing. -Acquires Target Research Associates, Inc., renamed Clinsys Inc.; a US based Clinical Research Organisation (CRO) -Acquires Trinity Laboratories, Inc. and its wholly owned subsidiary, Trigen Laboratories, Inc., renamed Jubilant Pharmaceuticals, Inc., a generic pharmaceutical company in USA having a US FDA approved formulations manufacturing facility -Enters Clinsys Clinical Research Ltd. business by setting up wholly owned subsidiary Jubilant Clinsys Ltd. 2006 -Selected as one of the top 25 companies for Institute of Company Secretaries of India National Award for Excellence in Corporate Governance -Finalist in Golden Peacock Award for Excellence in Corporate Governance -Company has splits its Face value of Shares from Rs 5 to Re 1 2007 -Jubilant Organosys Ltd has acquired 100% equity stake in Hollister-Stier Laboratories LLC, USA, engaged in high growth Injectable contract manufacturing and well established and stable Allergy Immunotherapy businesses. -Acquires Hollister Stier Laboratories in USA, a contract manufacturer of Sterile injectable vials and allergenic extracts. 2008 -Acquires DRAXIS Specialty Pharmaceuticals, Inc. Canada, a contract manufacturer of sterile & non-sterile products and radiopharmaceuticals -Acquires Speciality Molecules Pvt. Ltd. Engaged in the manufacturing of Fine Chemicals used by Life Science Industry including pharma, agro & cosmetic industry. -Jubilant Organosys and Lilly form Drug development joint venture - Uttar Pradesh-based pharma major Jubilant Organosys Ltd (JOL) has secured new contracts worth $92 million (Rs.3.7 billion). The contracts have been signed under Customs Research and Manufacturing Services (CRAMS). Besides marketing its products in the regulated markets of the US, Europe and Japan, the company has managed to make forays into China, said a statement of JOL. 2009 -Jubilant enters into multiple Drug discovery partnerships with leading pharma and biotech -companies such as AstraZeneca, Orion, Endo pharmaceuticals & BioLeap and also extends its collaboration with Lilly for five years. -Jubilant enters into drug development collaborations with academia, University of Alabama at Birmingham and Southern Research Institute (USA) and Duke University (Singapore). -Jubilant Kalpataru - 120 bed super specialty hospital at Barasat, Kolkata, India inaugurated by Hon'ble Minister of Finance Shri Pranab Mukherjee 2010 -ET - IMEA 2009 Platinum Award by Frost & Sullivan, in the Pharmaceutical category for the API facility at Nanjangud -Best CFO (FMCG, Health and Retail Sector) to Mr. R. Sankaraiah by Institute of Chartered Accountants of India in January, 2010 - Jubilant Organosys Ltd has appointed Mr. Shardul S. Shroff as Additional Director of the Company with effect from March 15, 2010. - Jubilant Organosys Ltd has signed a USD 51 million CRAMS contract with a leading Life Sciences Company 2010 -The Company has changed from "Jubilant Organosys Ltd" to "JUBILANT LIFE SCIENCES LTD" -Mr. Shardul S. Shroff has been appointed as Additional Director of the Company. 2011 -Jubilant Life Sciences Ltd has announced another successful delivery of an early stage milestone in the Pain therapeutic area. -Jubilant Org - Jubilant sets up global scale capacities for Symtet - developed through 2012 -JubilantLife - announced today that they have achieved an early stage milestone in one of their collaborative programs with Chadds Ford. -"Jubilant HollisterStier Announces Multi-Million Dollar Award for the manufacture of Sterile Parenteral Products". -"Jubilant SEZ at Bharuch, inaugurated by Shri Narendra Modi, Hon'ble Chief Minister of Gujarat". 2013 - "Jubilant Life Sciences receives prestigious NDTV Profit Business Leadership Award 2012 for Corporate Social Responsibility." - Jubilant Life Sciences receives ANDA approval for Quetiapine Fumarate Tablet -Jubilant Life Sciences declared winner of Supply Chain Excellence Awards' at 7th Express, Logistics & Supply Chain Leadership Awards 2013 2014 - Jubilant Life Scienc - Results of Tender Offer for acquisition of minority shares of Cadista Holdings Inc. - Board recommended a Dividend of Rs.3 per equity shares of Rs.1 -Jubilant Life Sciences wins Excellence Awards at `India Pharma Awards' 2014 -Jubilant Life Sciences conferred with Golden Peacock Business Excellence Award-2014 2015 -Gold Award in Ankleshwar Chapter Convention on Quality Concepts 2015 (ACCQC) -Two Honors at the 10th Annual CIO100 Awards by CIO Magazine - CIO100 Innovation Architect Special Awards 2015 and Versatile 100honorees -Golden Peacock National Quality Award for Quality -Dataquest Business Technology Awards for Best IT Implementation in Analytics, Mobility, Cloud, ERP/CSM/CRM -ASSOCHAM's `Responsible Organization Excellence' Award 2014-15 -50 Most Talented Sustainability Leaders Award -15th Annual Greentech Environment Award 2014 - Gold Category winner under Chemicals and Pharmaceutical sector" - Gajraula plant, India -I.C.O.N.I.C IDC Insights Award, under `Health and Life Sciences vertical 2016 - Jubilant Life Sciences Limited won the Sustainability Award for Best Green Process in Chemical sector of FICCI Chemicals & Petrochemicals Awards, 2016.

Registered Office

Bhartiagram, Gajraula

5924-252351,252356,252358,      5924-252352,

investors@jubl.com

http://www.jubl.com

Registrar Details

Alankit Assignment Ltd.